Double maintains 2 strategies that include SPRY - ARS Pharmaceuticals, Inc.
Current Value
$12.401 Year Return
Current Value
$12.401 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OPTN | 39.67% | $96.41M | -50.80% | 0.00% |
PRA | 38.29% | $1.19B | +58.17% | 0.00% |
AMRX | 36.19% | $2.35B | +11.11% | 0.00% |
ANAB | 36.09% | $599.36M | -19.91% | 0.00% |
ACLX | 35.17% | $3.22B | +10.72% | 0.00% |
LOAR | 35.12% | $7.83B | +64.87% | 0.00% |
RCUS | 35.08% | $907.43M | -50.92% | 0.00% |
KRYS | 34.59% | $3.77B | -20.42% | 0.00% |
APGE | 34.42% | $2.42B | -24.39% | 0.00% |
ENVA | 34.10% | $2.47B | +58.92% | 0.00% |
PFSI | 33.97% | $5.21B | +8.02% | 1.18% |
SYRE | 33.92% | $877.54M | -61.53% | 0.00% |
LGND | 33.91% | $2.00B | +21.70% | 0.00% |
SNDX | 33.77% | $770.13M | -57.22% | 0.00% |
IVZ | 33.64% | $6.86B | -4.79% | 5.38% |
INSG | 33.62% | $116.01M | +20.22% | 0.00% |
IMNM | 33.62% | $696.10M | -44.44% | 0.00% |
RMAX | 33.44% | $155.29M | -21.31% | 0.00% |
DY | 33.33% | $5.53B | +30.25% | 0.00% |
NDAQ | 33.33% | $46.66B | +30.61% | 1.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VGIT | 0.02% | $31.33B | 0.04% |
BNDX | -0.17% | $64.67B | 0.07% |
JPLD | 0.18% | $1.19B | 0.24% |
STXT | 0.20% | $134.15M | 0.49% |
SHY | 0.20% | $24.03B | 0.15% |
SHV | -0.24% | $20.94B | 0.15% |
STPZ | -0.24% | $446.46M | 0.2% |
KCCA | 0.34% | $97.18M | 0.87% |
WEAT | 0.38% | $115.83M | 0.28% |
IBMS | -0.41% | $69.47M | 0.18% |
IBTM | 0.44% | $313.33M | 0.07% |
BAB | 0.45% | $919.66M | 0.28% |
SCHR | 0.48% | $10.53B | 0.03% |
GOVT | -0.57% | $27.25B | 0.05% |
CGSM | 0.60% | $658.61M | 0.25% |
AGZ | -0.60% | $607.46M | 0.2% |
FXY | 0.61% | $838.61M | 0.4% |
TYA | 0.70% | $149.38M | 0.15% |
UTEN | 0.70% | $192.72M | 0.15% |
IBTL | -0.71% | $367.56M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VSA | -14.15% | $7.04M | -49.24% | 0.00% |
PULM | -9.16% | $23.82M | +239.64% | 0.00% |
K | -7.49% | $28.49B | +32.17% | 2.77% |
FMTO | -7.22% | $45.74M | -99.96% | 0.00% |
JOYY | -7.21% | $1.52B | +24.98% | 2.21% |
HSY | -6.41% | $33.16B | -21.37% | 3.44% |
TME | -6.05% | $11.45B | +5.62% | 1.90% |
GIS | -5.58% | $29.79B | -23.81% | 4.42% |
BTCT | -5.07% | $25.35M | +93.08% | 0.00% |
MSIF | -4.10% | $715.25M | +28.42% | 7.05% |
ZH | -3.51% | $319.69M | +2.30% | 0.00% |
PCRX | -3.17% | $1.19B | -18.76% | 0.00% |
AVD | -2.85% | $118.03M | -53.20% | 0.73% |
HUSA | -2.81% | $9.73M | -55.71% | 0.00% |
FIGS | -2.80% | $754.24M | -20.00% | 0.00% |
AQB | -2.67% | $2.96M | -61.58% | 0.00% |
UUU | -2.44% | $4.93M | +40.20% | 0.00% |
STG | -2.01% | $27.05M | -37.35% | 0.00% |
CBOE | -1.81% | $22.95B | +20.67% | 1.12% |
ARRY | -1.80% | $1.29B | -25.57% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CL | 0.06% | $72.64B | -5.18% | 2.25% |
KR | -0.11% | $44.68B | +24.17% | 1.89% |
RPAY | 0.18% | $342.61M | -61.94% | 0.00% |
VUZI | 0.19% | $200.52M | +75.33% | 0.00% |
RLMD | -0.24% | $13.72M | -88.15% | 0.00% |
VZ | 0.24% | $183.32B | +8.02% | 6.21% |
GME | 0.26% | $12.81B | +3.47% | 0.00% |
BNED | -0.28% | $371.19M | -38.80% | 0.00% |
VIPS | -0.37% | $6.31B | -15.50% | 3.26% |
OXBR | 0.38% | $14.89M | +14.29% | 0.00% |
TSN | -0.38% | $19.43B | -8.67% | 3.56% |
EH | 0.41% | $999.63M | +0.58% | 0.00% |
CQP | 0.45% | $29.63B | +27.28% | 5.30% |
VRSN | 0.46% | $26.45B | +64.74% | 0.00% |
VHC | -0.46% | $34.69M | +74.89% | 0.00% |
LITB | -0.57% | $21.28M | -72.45% | 0.00% |
PRPO | 0.74% | $10.84M | +15.14% | 0.00% |
OMCL | -0.75% | $1.32B | -11.31% | 0.00% |
RLX | 0.81% | $1.77B | -9.30% | 0.49% |
CYD | 0.86% | $643.06M | +106.88% | 2.24% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -32.82% | $109.64M | 0.85% |
TAIL | -29.14% | $140.49M | 0.59% |
BTAL | -22.73% | $361.41M | 1.43% |
USDU | -16.16% | $173.44M | 0.5% |
FTSD | -15.81% | $212.46M | 0.25% |
XONE | -15.54% | $603.24M | 0.03% |
UUP | -14.43% | $292.27M | 0.77% |
IBTG | -9.20% | $1.88B | 0.07% |
UNG | -8.80% | $371.83M | 1.06% |
CARY | -8.52% | $347.36M | 0.8% |
XBIL | -8.35% | $782.40M | 0.15% |
IVOL | -8.31% | $353.94M | 1.02% |
SCHO | -7.93% | $10.87B | 0.03% |
TBLL | -7.69% | $2.46B | 0.08% |
BIL | -7.08% | $45.95B | 0.1356% |
TPMN | -6.49% | $31.54M | 0.65% |
SPTS | -6.29% | $5.76B | 0.03% |
SHYM | -6.23% | $322.93M | 0.35% |
GBIL | -6.12% | $6.17B | 0.12% |
XHLF | -5.94% | $1.46B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 41.88% | $96.56M | 0.6% |
XBI | 41.27% | $4.85B | 0.35% |
IWC | 39.18% | $766.88M | 0.6% |
KJUL | 38.90% | $113.35M | 0.79% |
IWO | 37.54% | $11.36B | 0.24% |
XPH | 36.87% | $136.58M | 0.35% |
GNOM | 36.72% | $40.65M | 0.5% |
PINK | 36.55% | $131.52M | 0.5% |
VTWO | 36.48% | $12.07B | 0.07% |
IWM | 36.47% | $63.95B | 0.19% |
GSSC | 36.44% | $538.65M | 0.2% |
IFGL | 35.99% | $95.79M | 0.54% |
PSC | 35.92% | $811.78M | 0.38% |
XSMO | 35.90% | $1.51B | 0.39% |
ISCG | 35.80% | $645.00M | 0.06% |
SMMV | 35.73% | $305.76M | 0.2% |
ARKG | 35.59% | $944.78M | 0.75% |
PID | 35.44% | $831.69M | 0.53% |
SCHA | 35.33% | $16.91B | 0.04% |
KJAN | 35.24% | $305.13M | 0.79% |
Yahoo
One thing we could say about the analysts on ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) - they aren't optimistic, having...
Yahoo
Despite a successful product launch and expanded insurance coverage, ARS Pharmaceuticals Inc (SPRY) faces a net loss and anticipates significant operating expenses for 2025.
Yahoo
Q1 2025 ARS Pharmaceuticals Inc Earnings Call
SeekingAlpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ETCompany ParticipantsJustin Chakma - CBORichard Lowenthal -...
Yahoo
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held tod